Merck & Co. stock gains 1.06% to EUR 132.29 premarket
Published on 11/11/2026 at 08:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline news supports investor focus
- Merck reported positive Phase 2b results for efinopegdutide in adults with MASH and stage F2 or F3 liver fibrosis.
- The company is advancing additional growth drivers in HIV, COPD and oncology as investors assess longer-term pipeline execution.
Merck & Co. stock traded at EUR 132.29 on Lang & Schwarz at 08:14 CET on Wednesday, November 11, 2026, 1.06 percent above the Xetra close of Tuesday, November 10, at EUR 130.90.
The premarket move follows fresh attention on Merck's development pipeline. In a company release dated November 9, Merck said its Phase 2b efinopegdutide trial produced statistically significant MASH resolution without worsening of fibrosis at 52 weeks. The investigational weekly treatment is being evaluated in adults with stage F2 or F3 liver fibrosis.
The update adds a potential liver-disease growth driver to a pipeline already drawing attention in HIV, COPD and oncology. Recent company developments include the global Phase 3 ENHANCE-3 study of OHTUVAYRE for COPD maintenance treatment and regulatory progress for sacituzumab tirumotecan in endometrial cancer.
For investors, the pipeline is increasingly important as Merck balances new launches against longer-term competitive pressure on established products. The clinical data may strengthen the case for continued execution, while development, regulatory and commercial milestones remain key factors for the shares.
Broader sentiment can be tracked through the S&P 500.
More news and analyses are available on More news and analyses on Merck & Co. stock.
